Late Stage Lung Cancer Treated by Percutaneous Branched Pulmonary Artery Catheter Injected with Biological Preparations
Mao Aiwu Xu Zhiming Gao Zhongdu Qian Xigui Sun Jiazheng Shao Weicheng Shanghai Luke's Hospital (Shanghai 200050)
In this article, we discussed anti-tumor effect of Interleukin- I (IL-2) and Lymphokin - activated Killer (LAK) cells, as in local percutaneous irans-catheter intervention application , and intended to seek an application of biotherapy, of which having both definate therapeutic effect and feasible manipulation in late stage lung cancer. Altogether 60 cases of late stage lung cancer, randomized into 3 groups. In therapeutic group, we did percutaneous branched pulmonary artery catheter through external jugular artery, with IL - 2,LAK cells and other chemotherapy drugs injected into in combination. In controled group 2, we gave only the same chemotherapy through peripheral vein. The effective rates (CR-f-PR) were-.therapeutic group 53. 5% ,controlled group 1 39. 8% and controlled group 2 33. 3%. It had been shown that: 1. when IL -2 and LAK calls and other chemotherapy drugs were used in combination . there would be a synergistic action of anti-tumor effect. 2. the local percutaneous trans-catheter intervention application of IL - 2 and LAK cells made up for their short half-time in human body, and made it possible for target tumor tissue acquiring higher dosage of immunological cells, thus help promote their anti-tumor effect.